November 7th 2025
Submission of the sNDA suggests a potential FDA decision on the dextromethorphan-bupropion combination sometime during the first quarter of 2026.
Adding Icosapent Ethyl to Statin Therapy Cuts Stroke Risk, Analysis of REDUCE-IT Trial Finds
March 17th 2021International Stroke Conference 2021: A new analysis of the landmark REDUCE-IT trial found that adding icosapent ethyl to treatment regimens that already include statins further reduces stroke risk.